Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

The study used gold-standard autopsy confirmation to show that a blood test for Alzheimer's disease accurately detected ...

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

A new study has found intermittent fasting could slow, or even reverse, the progression of Alzheimer’s disease.

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.